000127996 001__ 127996
000127996 005__ 20240228145528.0
000127996 0247_ $$2doi$$a10.1016/j.pan.2017.04.012
000127996 0247_ $$2pmid$$apmid:28462862
000127996 0247_ $$2ISSN$$a1424-3903
000127996 0247_ $$2ISSN$$a1424-3911
000127996 037__ $$aDKFZ-2017-04018
000127996 041__ $$aeng
000127996 082__ $$a610
000127996 1001_ $$0P:(DE-He78)26a1abb52680b59098feffc168b98fd5$$aBerger, Anne-Katrin$$b0$$eFirst author$$udkfz
000127996 245__ $$aHigh prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study.
000127996 260__ $$aAmsterdam$$bElsevier$$c2017
000127996 3367_ $$2DRIVER$$aarticle
000127996 3367_ $$2DataCite$$aOutput Types/Journal article
000127996 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533718763_22870
000127996 3367_ $$2BibTeX$$aARTICLE
000127996 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127996 3367_ $$00$$2EndNote$$aJournal Article
000127996 520__ $$aPancreatic cancer patients are at high risk for venous thromboembolic events (VTEs), and chemotherapy is a known additional risk factor. In this context, there is a controversial discussion whether prophylactic anticoagulation should be offered to all outpatients receiving chemotherapy.In this retrospective study, we analyzed incidental and symptomatic VTEs in 150 pancreatic cancer patients receiving either gemcitabine-based chemotherapy or chemotherapy according to the FOLFIRINOX protocol.VTEs were identified in 25% of patients, but were not associated with an adverse survival. There was no significant difference in VTE incidence between patients treated with gemcitabine-based chemotherapy or the more intensive FOLFIRINOX protocol. A commonly used risk score to predict VTEs in cancer patients did not predict the occurrence of VTEs in our patients. The occurrence of VTEs was not associated with one of the recently described pancreatic cancer subtypes.One quarter of pancreatic cancer patients treated with palliative chemotherapy develops symptomatic or incidental VTEs that cannot be predicted by type of chemotherapy, subtype of pancreatic cancer or a commonly used risk score. Further studies are necessary to identify patients at risk, and to better define which patients at risk should be treated with prophylactic anticoagulation.
000127996 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000127996 588__ $$aDataset connected to CrossRef, PubMed,
000127996 7001_ $$aSingh, Hans Martin$$b1
000127996 7001_ $$aWerft, Wiebke$$b2
000127996 7001_ $$aMuckenhuber, Alexander$$b3
000127996 7001_ $$0P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c$$aSprick, Martin$$b4
000127996 7001_ $$0P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2$$aTrumpp, Andreas$$b5
000127996 7001_ $$aWeichert, Wilko$$b6
000127996 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b7
000127996 7001_ $$aSpringfeld, Christoph$$b8
000127996 773__ $$0PERI:(DE-600)2043694-4$$a10.1016/j.pan.2017.04.012$$gVol. 17, no. 4, p. 629 - 634$$n4$$p629 - 634$$tPancreatology$$v17$$x1424-3903$$y2017
000127996 909CO $$ooai:inrepo02.dkfz.de:127996$$pVDB
000127996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)26a1abb52680b59098feffc168b98fd5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000127996 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000127996 9141_ $$y2017
000127996 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000127996 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127996 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPANCREATOLOGY : 2015
000127996 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127996 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127996 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127996 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127996 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127996 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127996 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127996 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000127996 9201_ $$0I:(DE-He78)V964-20160331$$kV964$$lNCT-KliHD$$x0
000127996 9201_ $$0I:(DE-He78)A010-20160331$$kA010$$lStammzellen und Krebs$$x1
000127996 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x2
000127996 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000127996 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x4
000127996 980__ $$ajournal
000127996 980__ $$aVDB
000127996 980__ $$aI:(DE-He78)V964-20160331
000127996 980__ $$aI:(DE-He78)A010-20160331
000127996 980__ $$aI:(DE-He78)D120-20160331
000127996 980__ $$aI:(DE-He78)L101-20160331
000127996 980__ $$aI:(DE-He78)L701-20160331
000127996 980__ $$aUNRESTRICTED